ATE209497T1 - Azithromycin enthaltende arzneiverabreichungsformen mit gesteuerter wirkstoffabgabe - Google Patents

Azithromycin enthaltende arzneiverabreichungsformen mit gesteuerter wirkstoffabgabe

Info

Publication number
ATE209497T1
ATE209497T1 AT95913923T AT95913923T ATE209497T1 AT E209497 T1 ATE209497 T1 AT E209497T1 AT 95913923 T AT95913923 T AT 95913923T AT 95913923 T AT95913923 T AT 95913923T AT E209497 T1 ATE209497 T1 AT E209497T1
Authority
AT
Austria
Prior art keywords
azithromycin
administration forms
active release
controlled active
medicinal administration
Prior art date
Application number
AT95913923T
Other languages
English (en)
Inventor
William J Curatolo
Hylar L Friedman
Richard W Korsmeyer
Mott Steven R Le
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22900590&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE209497(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE209497T1 publication Critical patent/ATE209497T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Detergent Compositions (AREA)
AT95913923T 1994-05-06 1995-04-13 Azithromycin enthaltende arzneiverabreichungsformen mit gesteuerter wirkstoffabgabe ATE209497T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23909494A 1994-05-06 1994-05-06
PCT/IB1995/000264 WO1995030422A1 (en) 1994-05-06 1995-04-13 Controlled-release dosage forms of azithromycin

Publications (1)

Publication Number Publication Date
ATE209497T1 true ATE209497T1 (de) 2001-12-15

Family

ID=22900590

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95913923T ATE209497T1 (de) 1994-05-06 1995-04-13 Azithromycin enthaltende arzneiverabreichungsformen mit gesteuerter wirkstoffabgabe

Country Status (42)

Country Link
US (2) US6068859A (de)
EP (1) EP0758244B2 (de)
JP (1) JP2977907B2 (de)
KR (1) KR100232297B1 (de)
CN (1) CN1096862C (de)
AP (1) AP548A (de)
AT (1) ATE209497T1 (de)
AU (1) AU680356B2 (de)
BG (1) BG63152B1 (de)
BR (1) BR9501929A (de)
CA (1) CA2189658C (de)
CO (1) CO4290346A1 (de)
CZ (1) CZ292360B6 (de)
DE (1) DE69524214T3 (de)
DK (1) DK0758244T4 (de)
DZ (1) DZ1880A1 (de)
ES (1) ES2163504T5 (de)
FI (1) FI964452A0 (de)
HR (1) HRP950277B1 (de)
HU (1) HUT77530A (de)
IL (3) IL113516A (de)
IS (1) IS4282A (de)
LV (1) LV11729B (de)
MA (1) MA23537A1 (de)
MX (1) MX9605419A (de)
MY (1) MY113059A (de)
NO (1) NO315453B1 (de)
NZ (1) NZ283160A (de)
OA (1) OA10320A (de)
PE (1) PE4796A1 (de)
PL (1) PL179910B1 (de)
PT (1) PT758244E (de)
RO (1) RO114740B1 (de)
RU (1) RU2130311C1 (de)
SI (1) SI9520049A (de)
SK (1) SK282854B6 (de)
TN (1) TNSN95051A1 (de)
TW (1) TW420616B (de)
UA (1) UA41995C2 (de)
UY (1) UY23958A1 (de)
WO (1) WO1995030422A1 (de)
ZA (1) ZA953627B (de)

Families Citing this family (207)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5605889A (en) 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
NZ283160A (en) * 1994-05-06 1998-07-28 Pfizer Azithromycin in a controlled release dosage form for treating microbiol infections
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US6548084B2 (en) 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
HRP970493A2 (en) * 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same
CA2271569C (en) * 1996-11-15 2003-01-28 Gary Lee Manring Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US6551616B1 (en) 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
US20040028735A1 (en) * 1997-11-14 2004-02-12 Unchalee Kositprapa Pharmaceutical formulation
US6306642B1 (en) * 1997-11-24 2001-10-23 Quidel Corporation Enzyme substrate delivery and product registration in one step enzyme immunoassays
KR100440553B1 (ko) * 1998-03-26 2004-07-15 후지사와 야꾸힝 고교 가부시키가이샤 서방성 제제
HK1046638B (zh) * 1998-06-03 2006-02-24 阿尔扎有限公司 提供药物长效治疗的方法和装置
DE19850445A1 (de) * 1998-11-02 2000-05-04 Falk Pharma Gmbh Arzneimittel zur topischen Behandlung entzündlicher Darmerkrankungen
AU1238500A (en) * 1998-11-02 2000-05-22 Alza Corporation Controlled delivery of active agents
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
ATE404178T1 (de) * 1999-02-10 2008-08-15 Pfizer Prod Inc Vorrichtung mit matrixgesteuerter wirkstofffreisetzung
US6878386B1 (en) * 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
CA2383212C (en) * 1999-09-02 2008-11-25 Nostrum Pharmaceuticals, Inc. Controlled release oral dosage suitable for oral administration
CA2393585C (en) * 1999-12-09 2007-07-03 The Boots Company Plc Therapeutic agents
PT1242055E (pt) * 1999-12-23 2008-07-02 Pfizer Prod Inc Forma de dosagem de fármaco baseada em hidrogel
MXPA02006335A (es) 1999-12-23 2002-12-13 Pfizer Prod Inc Forma de dosificacion de farmaco en capas impulsada por hidrogel.
IL141438A0 (en) * 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6991807B2 (en) * 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US20050175959A1 (en) * 2000-03-14 2005-08-11 Coll Partners Ltd. System for the controlled delivery of an active material to a dental site
IL135061A0 (en) * 2000-03-14 2001-05-20 Ahron Jodaikin Strategic targeted fluoridation and chemical treatment of teeth
US6569152B2 (en) 2000-03-21 2003-05-27 Farrington Pharmaceuticals, Llc Sustained release delivery systems for solutes
FR2811571B1 (fr) * 2000-07-11 2002-10-11 Flamel Tech Sa Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
MXPA03001771A (es) 2000-08-30 2003-06-04 Pfizer Prod Inc Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento.
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
GB0025208D0 (en) * 2000-10-13 2000-11-29 Euro Celtique Sa Delayed release pharmaceutical formulations
US20020197314A1 (en) 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
FR2821745B1 (fr) * 2001-03-09 2004-07-02 Ethypharm Lab Prod Ethiques Granules et granules enrobes au gout masque
AU2002248792B2 (en) * 2001-04-18 2006-09-21 Nostrum Pharmaceuticals Inc. A novel coating for a sustained release pharmaceutical composition
HRP20010301A2 (en) * 2001-04-27 2001-12-31 Pliva D D New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
EP1652851A1 (de) 2001-05-22 2006-05-03 Pfizer Products Inc. Neue Kristallforme von Azithromycin
US20080305173A1 (en) * 2001-07-31 2008-12-11 Beuford Arlie Bogue Amorphous drug beads
OA12845A (en) * 2001-08-21 2006-09-15 Pfizer Prod Inc Single dose azithromycin for treating respiratory infections.
US6673369B2 (en) * 2001-08-29 2004-01-06 Ranbaxy Laboratories Limited Controlled release formulation
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
EP1541134A3 (de) * 2001-10-18 2007-06-06 Teva Pharmaceutical Industries Limited Stabilisierte Azithromycin-Zusammensetzungen
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US7612112B2 (en) * 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
WO2003053428A1 (en) * 2001-12-20 2003-07-03 Pharmacia Corporation Controlled release dosage form having improved drug release properties
JP2005513099A (ja) * 2001-12-21 2005-05-12 ファイザー・プロダクツ・インク アジスロマイシンの直接的に圧縮可能な配合品
KR100669279B1 (ko) * 2001-12-21 2007-01-16 화이자 프로덕츠 인크. 아지트로마이신의 습식 제립 방법
RU2212242C1 (ru) * 2001-12-24 2003-09-20 Закрытое акционерное общество "Брынцалов-А" Антибиотик сумазид
MXPA04007433A (es) 2002-02-01 2004-10-11 Pfizer Prod Inc Procedimiento para preparar dispersiones solidas amorfas homogeneas de farmaco secadas por pulverizacion utilizando un dispositivo de secado por pulverizacion modificado.
JP2005526020A (ja) * 2002-02-01 2005-09-02 ファイザー・プロダクツ・インク アジスロマイシンの乾式造粒配合物
PL371593A1 (en) * 2002-02-01 2005-06-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
KR100540035B1 (ko) * 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
JP4698950B2 (ja) * 2002-04-09 2011-06-08 フラメル・テクノロジー アモキシシリンの改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
CN100553625C (zh) 2002-04-09 2009-10-28 弗拉梅技术公司 活性成分微囊的口服混悬液
RU2283116C2 (ru) * 2002-05-27 2006-09-10 Курский государственный медицинский университет Способ увеличения выживаемости изолированного кожного лоскута "на ножке" у животных с пониженным антиоксидантным фоном
WO2003105810A1 (en) * 2002-06-14 2003-12-24 Andrx Corporation Pharmaceutical compositions for drugs having ph-dependentsolubility
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
GB0214013D0 (en) * 2002-06-18 2002-07-31 Euro Celtique Sa Pharmaceutical product
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
US8980870B2 (en) * 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
US20040062778A1 (en) * 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
WO2004041244A2 (en) * 2002-10-30 2004-05-21 Pharmacia Corporation Oral extended release tablets and methods of making and using the same
US7351430B2 (en) * 2002-11-06 2008-04-01 Uluru Inc. Shape-retentive hydrogel particle aggregates and their uses
US7811605B2 (en) * 2002-11-06 2010-10-12 Uluru Inc. Method of formation of shape-retentive aggregates of gel particles and their uses
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
US20040114368A1 (en) * 2002-12-13 2004-06-17 Shyu Shing Jy Light device having rotatable or movable view
MXPA05006513A (es) 2002-12-16 2005-09-08 Kissei Pharmaceutical Farmaco solido para uso oral.
US7910128B2 (en) * 2003-01-03 2011-03-22 Supernus Pharmaceuticals, Inc. Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics
FR2850577B1 (fr) * 2003-02-03 2005-04-15 Ethypharm Sa Particules enrobees a gout masque, leur procede de preparation et comprimes orodispersibles contenant lesdites particules
RU2241985C1 (ru) * 2003-03-27 2004-12-10 Томский политехнический университет Способ количественного определения азитромицина дигидрата методом инверсионной вольтамперометрии
AU2004238253B2 (en) * 2003-05-06 2011-01-27 Nostrum Pharmaceuticals, Inc. Controlled release formulation of erythromycin derivatives
US7063862B2 (en) 2003-06-03 2006-06-20 Biokey, Inc. Pharmaceutical composition and method for treating
AU2004249211A1 (en) * 2003-06-16 2004-12-29 Andrx Pharmaceuticals, Llc Oral extended-release composition
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
JP2006528185A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
AU2004258949B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP2006528190A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
JP2005041838A (ja) * 2003-07-24 2005-02-17 Matsumoto Shika Univ バイオフィルム除去剤
US20050025829A1 (en) * 2003-07-29 2005-02-03 Kim Cherng-Ju Controlled drug release tablets
CL2004001884A1 (es) * 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP1653925A1 (de) 2003-08-11 2006-05-10 Advancis Pharmaceutical Corporation Robustes pellet
WO2005016278A2 (en) 2003-08-12 2005-02-24 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2005023184A2 (en) 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
MXPA06002455A (es) * 2003-09-02 2006-08-31 Pfizer Prod Inc Formas de dosificacion de liberacion sostenida de ziprasidona.
US8460710B2 (en) 2003-09-15 2013-06-11 Shionogi, Inc. Antibiotic product, use and formulation thereof
EP1694304A2 (de) * 2003-12-04 2006-08-30 Pfizer Products Inc. Multiteilchenförmige dosierformen von azithromycin durch verfahren auf flüssigkeitsbasis
CA2547597A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate compositions with improved stability
JP2007513147A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 押し出し機を使用して、好ましくはポロキサマーとグリセリドを含有する多粒子結晶性医薬組成物を製造するための噴霧凝結方法
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
WO2005053652A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
ATE399536T1 (de) * 2003-12-04 2008-07-15 Pfizer Prod Inc Verfahren zur herstellung von pharmazeutischen multiteilchenförmigen produkten
CN1889931A (zh) * 2003-12-04 2007-01-03 辉瑞产品公司 利用挤压器制备优选含泊洛沙姆和甘油酯的多重粒子阿奇霉素组合物的喷雾－冻凝方法
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
WO2005053654A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release dosage forms of azithromycin
US20040224019A1 (en) * 2004-03-03 2004-11-11 Adi Shefer Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
WO2005120585A1 (en) * 2004-06-04 2005-12-22 Case Western Reserve University Dual function polymer micelles
US20070224269A1 (en) * 2004-06-10 2007-09-27 Rubino Orapin P Controlled Release Pharmaceutical Formulation
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
AU2005269981A1 (en) 2004-07-02 2006-02-09 Bonck, John A Tablet for pulsed delivery
EP1799196B1 (de) 2004-10-08 2016-06-22 Forward Pharma A/S Pharmazeutische zusammensetzung mit kontrollierter freisetzung mit einem fumarsäureester
WO2006067576A1 (en) * 2004-12-21 2006-06-29 Pfizer Products Inc. Enteric coated azithromycin multiparticulates
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US10071060B2 (en) * 2005-07-08 2018-09-11 Bioventures, Llc Asymmetrically coated table
US8858993B2 (en) * 2005-07-25 2014-10-14 Metrics, Inc. Coated tablet with zero-order or near zero-order release kinetics
EP1749519A1 (de) * 2005-08-05 2007-02-07 Schering Aktiengesellschaft Arzneiform mit Retardtierter pH-unabhängiger Wirkstofffreisetzung für Wirkstoffe mit starker pH-abhängiger Löslichkeit
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
CA2634830A1 (en) * 2005-12-27 2007-07-05 Labopharm Inc. Degradable polymeric microsphere composition
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US20070191271A1 (en) * 2006-02-10 2007-08-16 Dow Pharmaceutical Sciences Method for stabilizing polypeptides lacking methionine
US20070243248A1 (en) * 2006-04-14 2007-10-18 Cherukuri S Rao Rapidly disintegrating solid oral dosage form of liquid dispersions
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
JP2009539866A (ja) * 2006-06-05 2009-11-19 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換エリスロマイシンアナログの調製および有用性
US7713549B2 (en) * 2006-06-30 2010-05-11 Board Of Trustees Of The University Of Arkansas Extended release perforated tablet
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US7910135B2 (en) * 2006-10-13 2011-03-22 Uluru Inc. Hydrogel wound dressing and biomaterials formed in situ and their uses
US20110052688A1 (en) * 2006-11-21 2011-03-03 San-Laung Chow Solid dispersion composition
US11116728B2 (en) 2006-11-30 2021-09-14 Bend Research, Inc. Multiparticulates of spray-coated drug and polymer on a meltable core
US10357462B2 (en) * 2006-11-30 2019-07-23 Ben Research, Inc. Multiparticulates of spray-coated drug and polymer on a meltable core
CN100441196C (zh) * 2006-12-15 2008-12-10 北京化工大学 一种制备微粉化阿奇霉素的方法
MX2009006114A (es) * 2007-03-02 2009-11-10 Meda Pharmaceuticals Inc Composiciones que comprenden carisoprodol y metodos de uso de las mismas.
US20080228268A1 (en) * 2007-03-15 2008-09-18 Uluru, Inc. Method of Formation of Viscous, Shape Conforming Gels and Their Uses as Medical Prosthesis
BRPI0700969A (pt) * 2007-03-22 2008-11-04 Ouro Fino Participacoes E Empr composição para o tratamento de afecções bacterianas e inflamatórias em animais de companhia
US7850453B2 (en) * 2007-08-08 2010-12-14 Coll Partners Ltd. Reshapable device for fixation at a dental site
US8124123B2 (en) * 2007-09-05 2012-02-28 Dow Pharmaceutical Sciences, Inc. Controlled release azithromycin solid dosages forms
WO2009046829A2 (en) 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Casoxin d as a therapeutic agent
EP2197463A2 (de) 2007-09-11 2010-06-23 Mondobiotech Laboratories AG Verwendung von rgdspasskp und optional angiotensin-ii als therapeutische mittel zur behandlung von z.b. infektionen mit s. pneumoniae
CA2699169A1 (en) 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Therapeutic uses of intermedin 47 and 53 peptides
EP2187953A2 (de) 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Verwendung eines peptids als therapeutikum
JP2010538981A (ja) 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 単独でまたはペプチドＧｌｙ−Ａｒｇ−Ｇｌｙ−Ａｓｐ−Ａｓｎ−Ｐｒｏ−ＯＨと組み合わせて用いる、治療剤としてのペプチドＨｉｓ−Ｓｅｒ−Ｌｅｕ−Ｇｌｙ−Ｌｙｓ−Ｔｒｐ−Ｌｅｕ−Ｇｌｙ−Ｈｉｓ−Ｐｒｏ−Ａｓｐ−Ｌｙｓ−Ｐｈｅの使用
CA2699177A1 (en) 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
KR20100058555A (ko) 2007-09-11 2010-06-03 몬도바이오테크 래보래토리즈 아게 치료제로서의 ｂｐｐ－ｂ의 용도
AU2008297874A1 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of secretin and optionally urodilatin as therapeutic agents
EP2188015A2 (de) 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Verwendung von salusin beta allein oder in kombination mit octreotid als therapeutisches mittel
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
DE102008022520A1 (de) * 2008-05-07 2009-11-12 Bayer Animal Health Gmbh Feste Arzneimittelformulierung mit verzögerter Freisetzung
MX2010012039A (es) 2008-05-09 2010-11-30 Gruenenthal Gmbh Proceso para la preparacion de una formulacion de polvo intermedia y una forma de dosificacion solida final bajo el uso de un paso de congelacion por rocio.
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
EP2198859A1 (de) * 2008-12-17 2010-06-23 Losan Pharma GmbH Schmelzbeschichtete pharmazeutische Zusammensetzung mit Freisetzung
BR112012001547A2 (pt) 2009-07-22 2016-03-08 Gruenenthal Gmbh forma de dosagem farmacêutica extrusada por fusão a quente
ES2428938T3 (es) 2009-07-22 2013-11-12 Grünenthal GmbH Forma de dosificación resistente a la manipulación y estabilizada frente a la oxidación
JP2013509963A (ja) 2009-11-09 2013-03-21 スポットライト テクノロジー パートナーズ エルエルシー 断片化ヒドロゲル
JP5864429B2 (ja) 2009-11-09 2016-02-17 スポットライト テクノロジー パートナーズ エルエルシーＳｐｏｔｌｉｇｈｔ Ｔｅｃｈｎｏｌｏｇｙ Ｐａｒｔｎｅｒｓ Ｌｌｃ 架橋ヒドロゲル組成物、ヒドロゲル組成物の形成方法、及びキット
RU2567049C2 (ru) 2010-03-15 2015-10-27 Ульрих ДИТЦ Применение нитрокарбоновых кислот для лечения, диагностики и профилактики агрессивных форм заживления
WO2011125075A2 (en) 2010-04-08 2011-10-13 Fdc Limited A novel gastroretentive delivery of macrolide
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
CN103179954A (zh) 2010-09-02 2013-06-26 格吕伦塔尔有限公司 包含阴离子聚合物的抗破碎剂型
ES2645769T3 (es) 2011-01-05 2017-12-07 Hospira, Inc. Secado por pulverización de la vancomicina
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
PL2736497T3 (pl) 2011-07-29 2018-01-31 Gruenenthal Gmbh Tabletka odporna na ingerencję, zapewniająca natychmiastowe uwalnianie leku
ES2558756T3 (es) * 2011-08-08 2016-02-08 Aptalis Pharma Limited Método para la prueba de disolución de composiciones sólidas que contienen enzimas digestivas
US10653631B2 (en) 2011-09-07 2020-05-19 Roland SAUR-BROSCH Optimal colon targeting technology
JP2014529630A (ja) 2011-09-07 2014-11-13 ザウラー−ブロシュ、ローラント 哺乳類の消化管における一つあるいは複数の物質の放出制御製剤
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
US20130172271A1 (en) * 2012-01-04 2013-07-04 Cynthia Fragale Pharmaceutical Spray Drying
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
PL2838512T3 (pl) 2012-04-18 2018-12-31 Grünenthal GmbH Farmaceutyczna postać dawkowania odporna na niewłaściwe użycie i odporna na uderzeniowe uwalnianie dawki
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
RU2498805C1 (ru) * 2012-07-23 2013-11-20 Открытое акционерное общество "Биосинтез" Твердая лекарственная форма азитромицина
EP2885045A4 (de) * 2012-08-20 2016-07-20 O Ray Pharma Inc Verfahren zur herstellung von arzneistoffformulierungen
CN103860515A (zh) * 2012-12-10 2014-06-18 中国科学院上海药物研究所 阿奇霉素渗透泵控释片及其制备方法
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
CN104177457A (zh) * 2013-05-23 2014-12-03 长春海悦药业有限公司 一种阿奇霉素药物原料及其制剂和用途
WO2014191396A1 (en) 2013-05-29 2014-12-04 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
MX371432B (es) 2013-05-29 2020-01-30 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido que contiene una o mas particulas.
EP3878445A3 (de) 2013-06-05 2021-10-27 Synchroneuron Inc. Acamprosat-formulierungen, verfahren zur verwendung davon und kombinationen damit
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
US9668844B2 (en) 2013-11-06 2017-06-06 Colldent Y.A Ltd Device for fixation at a dental site
WO2015078891A1 (en) 2013-11-26 2015-06-04 Farmaceutici Formenti S.P.A. Preparation of a powdery pharmaceutical composition by means of cryo-milling
US20150320690A1 (en) 2014-05-12 2015-11-12 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EP3148512A1 (de) 2014-05-26 2017-04-05 Grünenthal GmbH Gegen entsorgung von ethanolischer dosis gesicherte mehrfachpartikel
BR112017021475A2 (pt) 2015-04-24 2018-07-10 Gruenenthal Gmbh forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
WO2016201259A1 (en) * 2015-06-10 2016-12-15 Piedmont Pharmaceuticals Llc Injectable antibiotic formulations and use thereof
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
WO2018190621A1 (ko) * 2017-04-10 2018-10-18 성균관대학교 산학협력단 다공성 위체류층을 포함하는 서방성 제제 및 이의 제조방법
GB201904757D0 (en) * 2019-04-04 2019-05-22 Biorelevant Com Ltd Biorelevant composition
US20240091324A1 (en) 2019-10-11 2024-03-21 Anatara Lifesciences Ltd Gastrointestinal health composition
CN112326838A (zh) * 2020-11-10 2021-02-05 湖北省宏源药业科技股份有限公司 一种改善阿奇霉素胶囊溶出曲线的测定方法
CN113116859B (zh) * 2021-04-12 2022-08-30 海南普利制药股份有限公司 阿奇霉素丸芯包衣制剂
CN113985783B (zh) * 2021-10-29 2022-09-02 中山东菱威力电器有限公司 一种冰激淋料浆有无检测电路
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2471186A1 (fr) * 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4340582A (en) * 1981-01-15 1982-07-20 Abbott Laboratories Erythromycin base tablets
SI8110592A8 (en) * 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4434153A (en) * 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4522625A (en) * 1982-09-29 1985-06-11 Alza Corporation Drug dispenser comprising wall formed of semipermeable member and enteric member
PH19293A (en) * 1982-11-15 1986-03-04 Pfizer Epimeric azahomoerythromycin,pharmaceutical composition containing the same and method of use thereof
US4851231A (en) * 1982-12-13 1989-07-25 Alza Corporation System for delivering drug in selected environment of use
US4496322A (en) 1983-05-11 1985-01-29 University Of Toronto Innovations Foundation Benzoin antimicrobial dental varnishes
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US4863741A (en) * 1985-03-25 1989-09-05 Abbott Laboratories Tablet composition for drug combinations
DE3524572A1 (de) 1985-07-10 1987-01-15 Thomae Gmbh Dr K Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin und verfahren zu ihrer herstellung
ES2029851T3 (es) 1986-04-17 1992-10-01 Eltech Systems Corporation Electrodo con catalizador de platino en una pelicula superficial y utilizacion del mismo.
US4792448A (en) * 1987-06-11 1988-12-20 Pfizer Inc. Generic zero order controlled drug delivery system
IT1222309B (it) 1987-07-08 1990-09-05 Menarini Sas Utilizzazione di forme farmaceutiche per uso topico contenenti miocamicina per la terapia delle infezione da germi sensibili alla miocamicina stessa
RO107257B1 (ro) * 1987-07-09 1993-10-30 Pfizer Procedeu de obtinere a unui dihidrat de azitromicina, cristalin
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
US4925674A (en) * 1988-08-25 1990-05-15 Himedics, Inc. Amoxicillin microencapsulated granules
IL91398A (en) * 1988-08-30 1994-05-30 Pfizer Pharmaceutical delivery device comprising active substance surrounded by asymmetric membrane
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
ATE90202T1 (de) * 1989-02-16 1993-06-15 British Tech Group Wirkstoffabgabevorrichtung.
AU633617B2 (en) * 1989-07-18 1993-02-04 Alza Corporation Dispenser comprising ionophore
US5198220A (en) 1989-11-17 1993-03-30 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
US5173299A (en) 1989-11-17 1992-12-22 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
US5084267A (en) 1989-11-17 1992-01-28 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
US5230895A (en) 1990-05-01 1993-07-27 Copley Pharmaceutical Inc. Sustained released delivery system for use in the periodontal pocket
DE69131574T2 (de) * 1990-05-14 2000-05-04 Gary R. Jernberg Chirurgisches implantat und verfahren zum einbetten von chemotherapeutika
US5114718A (en) 1990-09-20 1992-05-19 The Procter & Gamble Company Sustained release compositions for treating periodontol disease
SE9201930D0 (sv) † 1992-06-24 1992-06-24 Astra Ab Gastric antibacterial treatment
TW271400B (de) * 1992-07-30 1996-03-01 Pfizer
CA2150019C (en) 1992-11-30 1999-01-05 Scott M. Herbig Supported liquid membrane delivery devices
EP0721324A1 (de) * 1993-10-01 1996-07-17 The Procter & Gamble Company Verwendung von azithromycin zur behandlung von paradontose bei erwachsenen und topische zubereitungen für die verwendung
US5605889A (en) † 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
NZ283160A (en) 1994-05-06 1998-07-28 Pfizer Azithromycin in a controlled release dosage form for treating microbiol infections
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US6984403B2 (en) † 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects

Also Published As

Publication number Publication date
DZ1880A1 (fr) 2002-02-17
MX9605419A (es) 1997-12-31
PL317106A1 (en) 1997-03-17
PE4796A1 (es) 1996-03-09
EP0758244B1 (de) 2001-11-28
CZ324296A3 (cs) 1998-04-15
RU2130311C1 (ru) 1999-05-20
DK0758244T4 (da) 2008-06-16
OA10320A (en) 1997-10-07
IL131308A (en) 2001-07-24
NO964678L (no) 1997-01-06
EP0758244B2 (de) 2008-02-13
NZ283160A (en) 1998-07-28
HRP950277A2 (en) 1997-10-31
TNSN95051A1 (fr) 1996-02-06
US20020044965A1 (en) 2002-04-18
AP548A (en) 1996-10-30
HU9603076D0 (en) 1997-01-28
BG63152B1 (bg) 2001-05-31
CA2189658A1 (en) 1995-11-16
CA2189658C (en) 2000-10-31
DE69524214D1 (de) 2002-01-10
NO964678D0 (no) 1996-11-05
FI964452L (fi) 1996-11-05
KR100232297B1 (ko) 1999-12-01
LV11729B (en) 1997-08-20
KR970702727A (ko) 1997-06-10
UY23958A1 (es) 1995-10-31
AU680356B2 (en) 1997-07-24
LV11729A (lv) 1997-04-20
JP2977907B2 (ja) 1999-11-15
EP0758244A1 (de) 1997-02-19
HUT77530A (hu) 1998-05-28
TW420616B (en) 2001-02-01
ZA953627B (en) 1996-11-05
AU2113195A (en) 1995-11-29
IL113516A (en) 2001-04-30
JPH09505609A (ja) 1997-06-03
ES2163504T3 (es) 2002-02-01
SK143296A3 (en) 1998-07-08
UA41995C2 (uk) 2001-10-15
PL179910B1 (pl) 2000-11-30
MY113059A (en) 2001-11-30
US7108865B2 (en) 2006-09-19
PT758244E (pt) 2002-04-29
BG100960A (bg) 1997-08-29
BR9501929A (pt) 1996-03-05
MA23537A1 (fr) 1995-12-31
IL113516A0 (en) 1995-07-31
DE69524214T3 (de) 2008-05-15
CZ292360B6 (cs) 2003-09-17
US6068859A (en) 2000-05-30
IS4282A (is) 1995-11-07
FI964452A7 (fi) 1996-11-05
DK0758244T3 (da) 2002-02-11
HRP950277B1 (en) 2002-06-30
IL131308A0 (en) 2001-01-28
WO1995030422A1 (en) 1995-11-16
SI9520049A (en) 1997-12-31
ES2163504T5 (es) 2008-05-16
RO114740B1 (ro) 1999-07-30
SK282854B6 (sk) 2002-12-03
NO315453B1 (no) 2003-09-08
CN1149831A (zh) 1997-05-14
CO4290346A1 (es) 1996-04-17
DE69524214T2 (de) 2002-05-23
CN1096862C (zh) 2002-12-25
AP9500735A0 (en) 1995-04-30
FI964452A0 (fi) 1996-11-05

Similar Documents

Publication Publication Date Title
ATE209497T1 (de) Azithromycin enthaltende arzneiverabreichungsformen mit gesteuerter wirkstoffabgabe
DE69622780D1 (de) Transdermales therapeutisches System mit kontrollierter Wirkstofffreisetzung
FI940850A7 (fi) Laite lääkkeen annostelemiseksi ihon kautta
DE69525148D1 (de) Pharmazeutische formulierung
ID28232A (id) Formulasi farmasi dengan pelepasan terkontrol
DE69319320D1 (de) Arzneimittelzubereitung mit verspätet einsetzender kontinuierlicher Freisetzung
ATA903696A (de) Elektrotransport-medikamentenverabreichung
DE69529598D1 (de) Arzneimittelenthaltende Manschette
DE69829254D1 (de) Arzneistoffzubereitung mit kontrollierter Wirkstofffreisetzungsrate
NO20013566L (no) Farmasoytisk preparat med regulert frigjoringsvirkning
PT101106A (pt) Dispositivo administrador
FI971279L (fi) Lääkkeitä
KR950028764A (ko) 아지스로마이신 투여 방법
NO930484L (no) Medikamentutleveringsanordning
DE3880593D1 (de) Arzneizubereitungen mit retardierter wirkstofffreisetzung.
FI924247A7 (fi) Annostusmuoto lääkkeen vapauttamiseksi suoleen
DE69302933D1 (de) Arzneimittelabgabesystem
TR27244A (tr) Ilac dagitim aleti.
DE59804823D1 (de) Arzneimittelformulierung mit kontrollierter wirkstofffreisetzung
DE68905573D1 (de) Leicht absorbierbare nb-818 enthaltende arzneizubereitung.
PT879051E (pt) Administracao transdermica de risperidona com velocidade controlada
DE69914472D1 (de) Levosimendanhaltige oral anzuwendende arzneimittel mit gesteuerter wirkstoffverabreichung
NO942228D0 (no) Ipsapiron-legemiddeltilberedning
BR9703132A (pt) Temporizador medicinal
SE9202787D0 (sv) Patientanslutning

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0758244

Country of ref document: EP

REN Ceased due to non-payment of the annual fee